Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Regen Biopharma Inc (RGBP)

Regen Biopharma Inc (RGBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Regen Biopharma Enters Consulting Agreements for Clinical Trial

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Regen Biopharma...

RGBP : 0.0005 (-16.67%)
Regen BioPharma Update on Orphan Drug Application for HemaXellerate Will Be Presented At Emerging Growth Conference on September 24, 2025   

SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) today announced the Company will be presenting an update on its application for Orphan Drug...

RGBP : 0.0005 (-16.67%)
RGBPP : 0.0041 (+32.26%)
Regen BioPharma Prepares Response For FDA Regarding Its Orphan Drug Application for HemaXellerate

SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) today announced the Company is in the process of addressing comments received by the U.S. Food...

RGBP : 0.0005 (-16.67%)
RGBPP : 0.0041 (+32.26%)
Regen BioPharma Explores Expanded Use of HemaXellerate for Chemotherapy-Induced Bone Marrow Suppression

Regen’s Approach Could Be Paradigm Shift in Supportive Oncology Care SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC PINK: RGBP) today announced its ongoing efforts to...

RGBP : 0.0005 (-16.67%)
RGBPP : 0.0041 (+32.26%)
Regen BioPharma Discusses Potential Impact of HemaXellerate on Chemotherapy Treament Market

SAN DIEGO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC ID: RGBP and RGBPP) today provided further insight into its planned Phase 1 clinical trial of  HemaXellerate , the company’s...

RGBP : 0.0005 (-16.67%)
RGBPP : 0.0041 (+32.26%)
Regen BioPharma, Inc. to Seek Orphan Drug Designation for Lead Product

An Orphan Drug Designation Could Provide Significant Benefits to Regen SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC Pink: RGBP and RGBPP) today provides further insight...

RGBP : 0.0005 (-16.67%)
RGBPP : 0.0041 (+32.26%)
Regen BioPharma, Inc. Expands Vision for Phase 1 Clinical Trial of HemaXellerate™

RGBP : 0.0005 (-16.67%)
RGBPP : 0.0041 (+32.26%)
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on May 9, 2024

/CNW/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP), a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies,...

RGBP : 0.0005 (-16.67%)
RGBPP : 0.0041 (+32.26%)
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on March 7, 2024

/CNW/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP), a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies,...

RGBP : 0.0005 (-16.67%)
RGBPP : 0.0041 (+32.26%)
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on February 7, 2024

/CNW/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP), a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies,...

RGBP : 0.0005 (-16.67%)
RGBPP : 0.0041 (+32.26%)

Barchart Exclusives

2 Warren Buffett Dividend Stocks to Scoop Up in April
Warren Buffett is known for favoring durable businesses with strong cash flows, the kind that can sustain and grow dividends over time. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.